LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 141

Search options

  1. Article ; Online: Successful treatment of immune checkpoint inhibitor-related periaortitis.

    Bührer, Elias D / Alberts, Ian L / Christ, Lisa / Özdemir, Berna C

    Swiss medical weekly

    2024  Volume 154, Page(s) 3631

    Abstract: We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging. ...

    Abstract We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging. Clinical, laboratory, and radiologic findings resulted in a diagnosis of immune checkpoint inhibitor-related periaortitis. Periaortitis is a rare disease presenting with fibro-inflammatory tissue around the aorta and may lead to serious complications. Immune checkpoint inhibitors were discontinued, and the patient was treated with glucocorticoids, leading to a complete resolution of the periaortitis. To our knowledge, this is only the third reported case of immune checkpoint inhibitor-related periaortitis.
    MeSH term(s) Humans ; Middle Aged ; Immune Checkpoint Inhibitors/adverse effects ; Nivolumab/adverse effects ; Melanoma/drug therapy ; Glucocorticoids/therapeutic use ; Positron Emission Tomography Computed Tomography ; Ipilimumab/adverse effects
    Chemical Substances Immune Checkpoint Inhibitors ; Nivolumab (31YO63LBSN) ; Glucocorticoids ; Ipilimumab
    Language English
    Publishing date 2024-02-15
    Publishing country Switzerland
    Document type Case Reports ; Journal Article
    ZDB-ID 2036179-8
    ISSN 1424-3997 ; 1424-7860
    ISSN (online) 1424-3997
    ISSN 1424-7860
    DOI 10.57187/s.3631
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.152: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: New thresholds in semi-quantitative [

    Knappe, Luisa / Bregenzer, Carola / Gözlügöl, Nasir / Mingels, Clemens / Alberts, Ian / Rominger, Axel / Caobelli, Federico

    European journal of nuclear medicine and molecular imaging

    2023  Volume 50, Issue 13, Page(s) 3890–3896

    Abstract: Aim: [: Methods: We retrospectively evaluated 100 patients (50 with LVV and 50 controls) who underwent [: Results: Of the 50 patients diagnosed with LVV, SA vessels were affected in 38 (76%), TA in 42 (84%) and IA vessels in 26 (52%). To-liver ... ...

    Abstract Aim: [
    Methods: We retrospectively evaluated 100 patients (50 with LVV and 50 controls) who underwent [
    Results: Of the 50 patients diagnosed with LVV, SA vessels were affected in 38 (76%), TA in 42 (84%) and IA vessels in 26 (52%). To-liver normalized values had higher diagnostic accuracy than non-normalized values (AUC always ≥ 0.90 vs. 0.74-0.89). For the SA vessels, best thresholds were 0.66 for SUV
    Conclusion: LAFOV [
    MeSH term(s) Humans ; Fluorodeoxyglucose F18 ; Positron Emission Tomography Computed Tomography ; Radiopharmaceuticals ; Retrospective Studies ; Vasculitis/diagnostic imaging
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Radiopharmaceuticals
    Language English
    Publishing date 2023-09-07
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 8236-3
    ISSN 1619-7089 ; 0340-6997 ; 1619-7070
    ISSN (online) 1619-7089
    ISSN 0340-6997 ; 1619-7070
    DOI 10.1007/s00259-023-06423-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1227: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: FDG imaging with long-axial field-of-view PET/CT in patients with high blood glucose-a matched pair analysis.

    Mingels, Clemens / Weissenrieder, Luis / Zeimpekis, Konstantinos / Sari, Hasan / Nardo, Lorenzo / Caobelli, Federico / Alberts, Ian / Rominger, Axel / Pyka, Thomas

    European journal of nuclear medicine and molecular imaging

    2024  

    Abstract: Purpose: High blood glucose (hBG) in patients undergoing [: Materials and methods: Oncologic patients with elevated blood glucose (≥ 8.0 mmol/l) and normal blood glucose (< 8.0 mmol/l, nBG) levels were matched for tumor entity, gender, age, and BMI. ... ...

    Abstract Purpose: High blood glucose (hBG) in patients undergoing [
    Materials and methods: Oncologic patients with elevated blood glucose (≥ 8.0 mmol/l) and normal blood glucose (< 8.0 mmol/l, nBG) levels were matched for tumor entity, gender, age, and BMI. hBG patients were further subdivided into two groups (BG 8-11 mmol/l and BG > 11 mmol/l). Tracer uptake in the liver, muscle, and tumor was evaluated. Furthermore, image quality was compared between long acquisitions (ultra-high sensitivity mode, 360 s) on a LAFOV PET/CT and routine acquisitions equivalent to a short-axial field-of-view scanner (simulated (sSAFOV), obtained with high sensitivity mode, 120 s). Tumor-to-background ratio (TBR) and contrast-to-noise ratio (CNR) were used as the main image quality criteria.
    Results: Thirty-one hBG patients met the inclusion criteria and were matched with 31 nBG patients. Overall, liver uptake was significantly higher in hBG patients (SUV
    Conclusion: While elevated blood glucose (> 11 mmol) negatively affected TBR and CNR in our cohort, the images from a LAFOV PET-scanner had comparable CNR to PET-images acquired from nBG patients using sSAFOV PET/CT. Therefore, we argue that oncologic patients with increased blood sugar levels might be imaged safely with LAFOV PET/CT when rescheduling is not feasible.
    Language English
    Publishing date 2024-02-22
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 8236-3
    ISSN 1619-7089 ; 0340-6997 ; 1619-7070
    ISSN (online) 1619-7089
    ISSN 0340-6997 ; 1619-7070
    DOI 10.1007/s00259-024-06646-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1227: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Effects of natural products on cisplatin ototoxicity and chemotherapeutic efficacy.

    Rybak, Leonard P / Alberts, Ian / Patel, Shree / Al Aameri, Raheem F H / Ramkumar, Vickram

    Expert opinion on drug metabolism & toxicology

    2023  Volume 19, Issue 9, Page(s) 635–652

    Abstract: Introduction: Cisplatin is a very effective chemotherapeutic agent against a variety of solid tumors. Unfortunately, cisplatin causes permanent sensorineural hearing loss in at least two-thirds of patients treated. There are no FDA approved drugs to ... ...

    Abstract Introduction: Cisplatin is a very effective chemotherapeutic agent against a variety of solid tumors. Unfortunately, cisplatin causes permanent sensorineural hearing loss in at least two-thirds of patients treated. There are no FDA approved drugs to prevent this serious side effect.
    Areas covered: This paper reviews various natural products that ameliorate cisplatin ototoxicity. These compounds are strong antioxidants and anti-inflammatory agents. This review includes mostly preclinical studies but also discusses a few small clinical trials with natural products to minimize hearing loss from cisplatin chemotherapy in patients. The interactions of natural products with cisplatin in tumor-bearing animal models are highlighted. A number of natural products did not interfere with cisplatin anti-tumor efficacy and some agents actually potentiated cisplatin anti-tumor activity.
    Expert opinion: There are a number of natural products or their derivatives that show excellent protection against cisplatin ototoxicity in preclinical studies. There is a need to insure uniform standards for purity of drugs derived from natural sources and to ensure adequate pharmacokinetics and safety of these products. Natural products that protect against cisplatin ototoxicity and augment cisplatin's anti-tumor effects in multiple studies of tumor-bearing animals are most promising for advancement to clinical trials. The most promising natural products include honokiol, sulforaphane, and thymoquinone.
    Language English
    Publishing date 2023-10-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2214462-6
    ISSN 1744-7607 ; 1742-5255
    ISSN (online) 1744-7607
    ISSN 1742-5255
    DOI 10.1080/17425255.2023.2260737
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6264: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Large language models (LLM) and ChatGPT: what will the impact on nuclear medicine be?

    Alberts, Ian L / Mercolli, Lorenzo / Pyka, Thomas / Prenosil, George / Shi, Kuangyu / Rominger, Axel / Afshar-Oromieh, Ali

    European journal of nuclear medicine and molecular imaging

    2023  Volume 50, Issue 6, Page(s) 1549–1552

    MeSH term(s) Humans ; Nuclear Medicine ; Radionuclide Imaging
    Language English
    Publishing date 2023-03-09
    Publishing country Germany
    Document type Editorial ; Comment
    ZDB-ID 8236-3
    ISSN 1619-7089 ; 0340-6997 ; 1619-7070
    ISSN (online) 1619-7089
    ISSN 0340-6997 ; 1619-7070
    DOI 10.1007/s00259-023-06172-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1227: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.

    Alberts, Ian / Bütikofer, Lukas / Rominger, Axel / Afshar-Oromieh, Ali

    PloS one

    2022  Volume 17, Issue 7, Page(s) e0270269

    Abstract: Background: A number of radiopharmaceuticals are available for the detection of recurrent prostate cancer (rPC), but few comparative imaging trials have been performed comparing them. In particular, there are no prospective head-to-head comparisons of ... ...

    Abstract Background: A number of radiopharmaceuticals are available for the detection of recurrent prostate cancer (rPC), but few comparative imaging trials have been performed comparing them. In particular, there are no prospective head-to-head comparisons of the recently introduced [18F]PSMA-1007 to the existing standard of care [68Ga]Ga-PSMA-11. The purpose of this trial is to establish the non-inferiority of the new radiopharmaceutical in terms of the rate of PET-positive findings and to obtain an intra-individual comparison of accuracy and radiopharmaceutical kinetics.
    Methods: In this cross-over trial we will randomise 100 individuals to receive either first a standard-of-care PET/CT using [68Ga]Ga-PSMA-11 followed by an additional [18F]PSMA-1007 PET/CT within 2 weeks, or vice-versa. Inclusion criteria include patients 18 years and older with biochemical recurrence of prostate cancer following radical prostatectomy, defined as two consecutive prostate specific antigen (PSA) levels > 0.2 ng/ml. Detection rate at the patient-based level is the primary end-point. Each scan will be interpreted by a panel of six independent and masked readers (three for [68Ga]Ga-PSMA-11 and three for [18F]PSMA-1007) which consensus majority in cases of discrepancy. To confirm the PET-positivity rate at a patient based level, follow up at 6 months following the first scan will be performed to a composite standard of truth. Secondary endpoints shall include an intra-individual comparison of radiopharmaceutical-kinetics, per-region detection rate and positive predictive value.
    Discussion: This is the first randomised prospective comparative imaging trial to compare the established [68Ga]Ga-PSMA-11 with [18F]PSMA-1007 and will determine whether the new radiopharmaceutical is non-inferior to the established standard-of-care in terms of patient-level detection rate.
    Clinical trial registration: Registered with and approved by the regional ethics authority #2020-02903 (submitted 09.12.2020, approval 16.12.2021) and the regulatory authority SwissMedic 2020DR2103. Registered with ClinicalTrials.gov Identifier NCT05079828 and additionally in a national language in the Swiss National Clinical Trials Portal (SNCTP).
    MeSH term(s) Edetic Acid ; Gallium Radioisotopes ; Humans ; Ligands ; Male ; Neoplasm Recurrence, Local/diagnostic imaging ; Niacinamide/analogs & derivatives ; Oligopeptides ; Positron Emission Tomography Computed Tomography/methods ; Prostate-Specific Antigen ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/surgery ; Radiopharmaceuticals ; Randomized Controlled Trials as Topic
    Chemical Substances Gallium Radioisotopes ; Ligands ; Oligopeptides ; PSMA-1007 ; Radiopharmaceuticals ; Niacinamide (25X51I8RD4) ; Edetic Acid (9G34HU7RV0) ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2022-07-19
    Publishing country United States
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0270269
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Single time point quantitation of cerebral glucose metabolism by FDG-PET without arterial sampling.

    Cumming, Paul / Dias, André H / Gormsen, Lars C / Hansen, Allan K / Alberts, Ian / Rominger, Axel / Munk, Ole L / Sari, Hasan

    EJNMMI research

    2023  Volume 13, Issue 1, Page(s) 104

    Abstract: Background: Until recently, quantitation of the net influx of 2-[: Results: Correlation analysis of the coefficients of a tri-exponential decomposition of the IDIFs measured during 67 min revealed strong relationships among the total area under the ... ...

    Abstract Background: Until recently, quantitation of the net influx of 2-[
    Results: Correlation analysis of the coefficients of a tri-exponential decomposition of the IDIFs measured during 67 min revealed strong relationships among the total area under the curve (AUC), the terminal normalized arterial integral (theta
    Conclusions: The observed interrelationships between pharmacokinetic parameters in the IDIF measured during the PET recording support quantitation of FDG-K
    Language English
    Publishing date 2023-11-30
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2619892-7
    ISSN 2191-219X
    ISSN 2191-219X
    DOI 10.1186/s13550-023-01049-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Authors' reply to Dr. Paolo Duarte: Combined [68Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.

    Alberts, Ian / Schepers, Robin / Zeimpekis, Konstantinos / Sari, Hasan / Rominger, Axel / Afshar-Oromieh, Ali

    European journal of nuclear medicine and molecular imaging

    2022  Volume 50, Issue 3, Page(s) 644–647

    MeSH term(s) Humans ; Positron Emission Tomography Computed Tomography ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Positron-Emission Tomography
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; gallium 68 PSMA-11 ; Gallium Radioisotopes ; Lutetium-177 (BRH40Y9V1Q)
    Language English
    Publishing date 2022-12-22
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 8236-3
    ISSN 1619-7089 ; 0340-6997 ; 1619-7070
    ISSN (online) 1619-7089
    ISSN 0340-6997 ; 1619-7070
    DOI 10.1007/s00259-022-06071-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1227: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Synthesis, pharmacological evaluations, and molecular docking studies on a new 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework: Rigidification of D

    Giri, Rajan / Alberts, Ian / Harding, Wayne W

    Chemical biology & drug design

    2020  Volume 96, Issue 2, Page(s) 825–835

    Abstract: The novel 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework, a structurally rigidified variant of the 1-phenylbenzazepine template, was synthesized via direct arylation as a key reaction. Evaluation of the binding affinities of the rigidified ... ...

    Abstract The novel 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework, a structurally rigidified variant of the 1-phenylbenzazepine template, was synthesized via direct arylation as a key reaction. Evaluation of the binding affinities of the rigidified compounds across a battery of serotonin, dopamine, and adrenergic receptors indicates that this scaffold unexpectedly has minimal affinity for D
    MeSH term(s) 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/chemistry ; Azepines/chemistry ; Benzazepines/chemistry ; Dopamine Agonists/chemistry ; Hydrogen Bonding ; Ligands ; Molecular Conformation ; Molecular Docking Simulation ; Protein Binding ; Receptors, Dopamine D1/chemistry ; Receptors, Serotonin/chemistry ; Structure-Activity Relationship
    Chemical Substances 1-phenylbenzazepine ; Azepines ; Benzazepines ; Dopamine Agonists ; Ligands ; Receptors, Dopamine D1 ; Receptors, Serotonin ; serotonin 6 receptor ; SK&F 75670 (62717-63-9) ; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (67287-49-4)
    Language English
    Publishing date 2020-04-22
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2216600-2
    ISSN 1747-0285 ; 1747-0277
    ISSN (online) 1747-0285
    ISSN 1747-0277
    DOI 10.1111/cbdd.13691
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Prostate Cancer Theranostics: PSMA Targeted Therapy.

    Seifert, Robert / Alberts, Ian L / Afshar-Oromieh, Ali / Rahbar, Kambiz

    PET clinics

    2021  Volume 16, Issue 3, Page(s) 391–396

    Abstract: Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, ... ...

    Abstract Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, especially in advanced metastasized castration-resistant prostate cancer. Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. The aim of this review is to provide an overview of the history and current and future developments of PSMA-targeted therapy. A special focus of this review is on PSMA PET-guided management of patients receiving PSMA-targeted radioligand therapy.
    MeSH term(s) Humans ; Male ; Multicenter Studies as Topic ; Precision Medicine ; Prospective Studies ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/therapy ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Retrospective Studies ; Theranostic Nanomedicine
    Language English
    Publishing date 2021-05-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2764575-7
    ISSN 1879-9809 ; 1556-8598
    ISSN (online) 1879-9809
    ISSN 1556-8598
    DOI 10.1016/j.cpet.2021.03.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Einzelsignatur: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top